Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study

Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study

Abstract Background Guselkumab is a selective interleukin (IL)-23 inhibitor targeting the IL-23p19 subunit. In the phase 3b COSMOS trial, guselkumab demonstrated efficacy in treating participants with active psoriatic arthritis (PsA) and inadequate response (IR; lack of efficacy or intolerance) to t...

Full description

Bibliographic Details
Main Authors: Georg Schett, Warner Chen, Sheng Gao, Soumya D. Chakravarty, May Shawi, Frederic Lavie, Miriam Zimmermann, Mohamed Sharaf, Laura C. Coates, Stefan Siebert
Format: Article
Language:English
Published: BMC 2023-08-01
Series:Arthritis Research & Therapy
Subjects:
Serum biomarkers
IL-23/IL-17 pathway
Guselkumab
Psoriatic arthritis
Online Access:https://doi.org/10.1186/s13075-023-03125-4

Internet

https://doi.org/10.1186/s13075-023-03125-4

Similar Items